As part of the structural change project “Innovation Region Central Germany”, eleven projects were recently launched to shape structural change in the region. Among them is the QualiBioPharma project, which is significantly supported by the Office for Economic Development and the Department for Employment Policy of the City of Leipzig. The qualification and further training programme for pharmaceutical laboratory assistants aims to cover the already existing and growing demand for skilled workers of biotechnological companies in Central Germany.
“We are pleased that we will gain more specialists with this project, because our biotechnology companies urgently need qualified laboratory assistants in order to continue to grow. And for international, innovative life science companies looking for a new location, well-trained specialists are another important argument for a positive location decision for Leipzig as a business location,” says Clemens Schülke, acting head of the Department of Economics, Labour and Digital affairs of the City of Leipzig.
“Not only since the corona crisis have we been aware of the importance of medical biotechnology for the region and the country. Over several years, a considerable research and development landscape has been successfully built up in Central Germany in this promising industry. QualiBioPharma is an important building block to realize the industrial exploitation of the achieved research results,” explains André Hofmann, Managing Director of biosaxony Management GmbH.
Jörn-Heinrich Tobaben, Managing Director of the European Metropolitan Region of Central Germany, is optimistic: “We see structural change as an opportunity. With such educational offers, we want to open up new perspectives on the labour market in Central Germany for the people affected by structural change in the Central German coalfield and thus keep skilled workers in the region.”
In the QualiBioPharma project, the five project partners biosaxony Management GmbH, Fraunhofer IZI, BioSolutions Halle, TGZ Halle and ATV will develop a qualification program for pharmaceutical laboratory technicians for lateral entrants. The first pilot run is planned for March to May 2022.
As part of QualiBioPharma, the five project partners biosaxony Management GmbH, Fraunhofer IZI, BioSolutions Halle, TGZ Halle and ATV are developing and testing a specialized training program to open up new perspectives on the labor market in Central Germany for employees from outside the industry who are affected by structural change. This will strengthen the regional skilled worker base in the life science industry. In addition, the metropolitan region can strengthen its competitive position as an international location for cell therapy and pharmacy and thus favors new large-scale settlements. Further information can be found on biosaxony’s website
QualiBioPharma emerged from the 2. Ideas competition as part of the structural change project “Innovation Region Central Germany” of the European Metropolitan Region of Central Germany. The project is funded with 166,000 Euros through the model project “Unternehmen Revier” of the Federal Ministry for Economic Affairs and Energy (BMWi). In addition, the project is supported by the Economic Development Agency and the Department for Employment Policy of the City of Leipzig.
About the structural change project “Innovation Region Central Germany”
In the project “Innovation Region Central Germany”, the European Metropolitan Region of Central Germany is developing new strategies and projects for structural change in the region with the districts of Altenburger Land, Anhalt-Bitterfeld, Burgenlandkreis, Leipzig, Mansfeld-Südharz, Nordsachsen and Saalekreis as well as the cities of Halle (Saale) and Leipzig. The project is funded by the federal government, the Free State of Saxony, the State of Saxony-Anhalt and the Free State of Thuringia as part of the federal-state joint task “Improvement of the Regional Economic Structure” (GRW).
Source: Press release biosaxony from 19.07.2021